MétaCan
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
Sort
Language
Type
Field
Venue
Topic
Gastric Cancer Management and Outcomes
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

1,089 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
1,089 works in the cohort · of 4,299,418page 8 of 22

Labels cover 5 of 1,089 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 1,089 of 1,089 works in this cohort. Predictions are machine_predicted_unvalidated teacher distillation outputs. Candidate is the union; consensus is the intersection.

affunlabeled
Updated results from the trastuzumab deruxtecan (T-DXd) 5.4 mg/kg triplet combination of DESTINY-Gastric03 (DG-03): First-line (1L) T-DXd with fluoropyrimidine (FP) and pembrolizumab in advanced/metastatic HER2-positive (HER2+) esophageal adenocarcinoma, gastric cancer (GC), or gastroesophageal junction adenocarcinoma (GEJA).
Yelena Y. Janjigian, Hanneke W. M. van Laarhoven, Sun Young Rha, Vadim Kozlov, Do-Youn Oh, Adriano Gravina +9 more
2025· article· en· Journal of Clinical Oncology· Medicine
distilled prediction:candidate · metaepi_narrowconsensus · none
8
citations
affno abstractunlabeled
Core curriculum for endoscopic mucosal resection
Hiroyuki Aihara, Vladimir Kushnir, Gobind Anand, Lisa Cassani, Prabhleen Chahal, Sunil Dacha +13 more
2020· article· en· Gastrointestinal Endoscopy· Medicine
distilled prediction:candidate · noneconsensus · none
8
citations
affunlabeled
S9511
Charles D. Blanke, Kari Chansky, Kathy Christman, Scott A. Hundahl, Brian F. Issell, Peter J. Van Veldhuizen +3 more
2010· article· en· American Journal of Clinical Oncology· Medicine
distilled prediction:candidate · noneconsensus · none
7
citations

How this was built: Screen · Findings · About